adenine has been researched along with Lymphocytopenia in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Limited data have been published about the infection risk associated with these new drugs, therefore this study analyzes the infectious complications in patients with lymphoproliferative diseases (LPD) treated with monoclonal antibodies (obinutuzumab, ofatumumab, brentuximab, nivolumab, or pembrolizumab), BTK inhibitors (ibrutinib and acalabrutinib), PI3K inhibitors (idelalisib) and BCL2 inhibitors (venetoclax)." | 4.02 | Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. ( Alonso, C; Ángel Hernández-Rivas, J; Bastidas, G; Bastos-Oreiro, M; Bocanegra, A; Carpio, C; Comai, A; Cordoba, R; De Nicolás, R; Del Campo, R; Fernández-Cruz, A; García-Suárez, J; Grande, C; Jiménez-Ubieto, A; López-Guillermo, A; López-Jiménez, J; Luis Plana, J; Marquet, J; Martín, X; Martínez-López, J; Mas-Ochoa, C; Morillo, D; Navarro-Matilla, B; Núñez, L; Prat, M; Romero, S; Ruiz-Camps, I; Seri, C; Serna, Á; Stefania Infante, M; Vásquez, L; Villafuerte, P, 2021) |
| "Invasive bacterial infections developed in 23 (53." | 1.48 | Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. ( Cohen, N; Hohl, TM; Palomba, ML; Redelman-Sidi, G; Seo, SK; Taur, Y; Varughese, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Stefania Infante, M | 1 |
| Fernández-Cruz, A | 1 |
| Núñez, L | 1 |
| Carpio, C | 1 |
| Jiménez-Ubieto, A | 1 |
| López-Jiménez, J | 1 |
| Vásquez, L | 1 |
| Del Campo, R | 1 |
| Romero, S | 1 |
| Alonso, C | 1 |
| Morillo, D | 1 |
| Prat, M | 1 |
| Luis Plana, J | 1 |
| Villafuerte, P | 1 |
| Bastidas, G | 1 |
| Bocanegra, A | 1 |
| Serna, Á | 1 |
| De Nicolás, R | 1 |
| Marquet, J | 1 |
| Mas-Ochoa, C | 1 |
| Cordoba, R | 1 |
| García-Suárez, J | 1 |
| Comai, A | 1 |
| Martín, X | 1 |
| Bastos-Oreiro, M | 1 |
| Seri, C | 1 |
| Navarro-Matilla, B | 1 |
| López-Guillermo, A | 1 |
| Martínez-López, J | 1 |
| Ángel Hernández-Rivas, J | 1 |
| Ruiz-Camps, I | 1 |
| Grande, C | 1 |
| Wang, ML | 1 |
| Jain, P | 1 |
| Zhao, S | 1 |
| Lee, HJ | 1 |
| Nastoupil, L | 1 |
| Fayad, L | 1 |
| Ok, CY | 1 |
| Kanagal-Shamanna, R | 1 |
| Hill, HA | 1 |
| Yao, Y | 1 |
| Hagemeister, FB | 1 |
| Westin, JR | 1 |
| Fowler, N | 1 |
| Samaniego, F | 1 |
| Steiner, R | 1 |
| Nair, R | 1 |
| Iyer, SP | 1 |
| Navsaria, L | 1 |
| Badillo, M | 1 |
| Feng, L | 1 |
| Xuelin, H | 1 |
| Nogueras Gonzalez, GM | 1 |
| Xu, G | 1 |
| Wagner-Bartak, N | 1 |
| Thirumurthi, S | 1 |
| Santos, D | 1 |
| Tang, G | 1 |
| Lin, P | 1 |
| Wang, SA | 1 |
| Jorgensen, J | 1 |
| Yin, CC | 1 |
| Li, S | 1 |
| Patel, KP | 1 |
| Vega, F | 1 |
| Medeiros, LJ | 1 |
| Flowers, CR | 1 |
| Wang, L | 1 |
| Baumann, T | 1 |
| Delgado, J | 1 |
| Montserrat, E | 1 |
| Varughese, T | 1 |
| Taur, Y | 1 |
| Cohen, N | 1 |
| Palomba, ML | 1 |
| Seo, SK | 1 |
| Hohl, TM | 1 |
| Redelman-Sidi, G | 1 |
| Chiriaco, M | 1 |
| Brigida, I | 1 |
| Ariganello, P | 1 |
| Di Cesare, S | 1 |
| Di Matteo, G | 1 |
| Taus, F | 1 |
| Cittaro, D | 1 |
| Lazarevic, D | 1 |
| Scarselli, A | 1 |
| Santilli, V | 1 |
| Attardi, E | 1 |
| Stupka, E | 1 |
| Giannelli, S | 1 |
| Fraziano, M | 1 |
| Finocchi, A | 1 |
| Rossi, P | 1 |
| Aiuti, A | 1 |
| Palma, P | 1 |
| Cancrini, C | 1 |
| UEBELIN, R | 1 |
| Kakuda, TN | 1 |
| Anderson, PL | 1 |
| Becker, SL | 1 |
| Barrios, A | 1 |
| Rendón, A | 1 |
| Negredo, E | 1 |
| Barreiro, P | 1 |
| Garcia-Benayas, T | 1 |
| Labarga, P | 1 |
| Santos, J | 1 |
| Domingo, P | 1 |
| Sánchez-Conde, M | 1 |
| Maida, I | 1 |
| Martín-Carbonero, L | 1 |
| Núñez, M | 1 |
| Blanco, F | 1 |
| Clotet, B | 1 |
| Sambeat, MA | 1 |
| Gil, P | 1 |
| Gonzalez-Lahoz, J | 1 |
| Cooper, D | 1 |
| Soriano, V | 1 |
| Lacombe, K | 1 |
| Pacanowski, J | 1 |
| Meynard, JL | 1 |
| Trylesinski, A | 1 |
| Girard, PM | 1 |
| Kefford, RF | 1 |
| Fox, RM | 1 |
| Hollingsworth, JW | 1 |
| Carr, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy[NCT02427620] | Phase 2 | 131 participants (Anticipated) | Interventional | 2015-06-03 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for adenine and Lymphocytopenia
| Article | Year |
|---|---|
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxoru | 2022 |
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
Topics: Adenine; Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, | 2005 |
9 other studies available for adenine and Lymphocytopenia
| Article | Year |
|---|---|
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.
Topics: Adenine; Adolescent; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies | 2021 |
CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Betacoronavi | 2020 |
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Bacterial Infections; Electronic Health Records; Female; Hu | 2018 |
The case of an APDS patient: Defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment.
Topics: Adenine; B-Lymphocytes; Cell Differentiation; Class I Phosphatidylinositol 3-Kinases; Dendritic Cell | 2017 |
[Adenine inhibition of the lymphocytopenia and the atrophy of the thymus appearing after the administration of glucose].
Topics: Adenine; Atrophy; Disease; Glucose; Humans; Lymphocytes; Lymphopenia; Thymus Gland | 1953 |
CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
Topics: Adenine; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Interactions; Drug Therapy, C | 2004 |
Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Po | 2005 |
Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
Topics: Adenine; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Cell Survival; Cells, Cultured; Coform | 1983 |
3H-uridine incorporation as a T lymphocyte indicator in the rat.
Topics: Adenine; Adenosine; Animals; Ascitic Fluid; Autoradiography; Cycloheximide; Cytidine; Dactinomycin; | 1973 |